Effects of inhibitors of arachidonic acid metabolism on serotonin release from rat basophilic leukemia cells.
Mast cells can release arachidonic acid (AA) metabolites as well as preformed mediators with IgE mediated stimulation, and these mediators are considered to play an important role in allergic reactions. The coincident release of preformed mediators and AA metabolites suggests that AA metabolism is related to mast cell degranulation. To clarify the relationship between mast cell degranulation and AA metabolism, the effects of various A cascade inhibitors on rat basophilic leukemia cell (RBL) mediator release induced by either anti-IgE or A23187 were examined. 5,8,11,14-eicosatetraynoic acid (ETYA) inhibited both PGD2 and LTC4/D4 generation, and partially inhibited serotonin release. Nordihydroguaiaretic acid (NDGA) caused complete inhibition of LTC4/D4 generation, and partial inhibition of PGD2 generation and serotonin release. The cyclooxygenase inhibitor, indomethacin, and the specific 5-lipoxygenase inhibitor, L-651,392 completely inhibited PGD2 and LTC4/D4 generation, respectively, without affecting release of other mediators. Both PGD2 and LTC4/D4 generation were abolished by the combination of indomethacin and L-651,392, however, serotonin release remained intact. HPLC analysis showed that no shift to other AA metabolites occurred after the treatment with these inhibitors. Mepacrine, a phospholipase A2 inhibitor, completely inhibited PGD2 and LTC4/D4 generation, as well as AA release itself, without affecting serotonin release. Therefore, neither AA metabolism nor AA release is necessary for RBL degranulation.
Allergic Diseases Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Y
Y
Igarashi
J D
JD
Lundgren
J H
JH
Shelhamer
M A
MA
Kaliner
M V
MV
White
D015117:5,8,11,14-Eicosatetraynoic Acid / Q000494:pharmacology; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D015471:Leukemia, Basophilic, Acute; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D009637:Masoprocol / Q000494:pharmacology; D008407:Mast Cells / Q000187:drug effects* / Q000378:metabolism; D010640:Phenothiazines / Q000494:pharmacology; D015230:Prostaglandin D2 / Q000378:metabolism; D051381:Rats; D013189:SRS-A / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism*; D014407:Tumor Cells, Cultured
D016861:Cyclooxygenase Inhibitors; D016859:Lipoxygenase Inhibitors; D010640:Phenothiazines; D013189:SRS-A; D015117:5,8,11,14-Eicosatetraynoic Acid; D016718:Arachidonic Acid; D012701:Serotonin; D009637:Masoprocol; C053726:4-bromo-2,7-dimethoxy-3H-phenothiazin-3-one; D015230:Prostaglandin D2; D007213:Indomethacin